These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 9127633

  • 1. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
    Lissoni P, Barni S, Brivio F, Rossini F, Fumagalli L, Tancini G.
    J Biol Regul Homeost Agents; 1995; 9(2):52-4. PubMed ID: 9127633
    [Abstract] [Full Text] [Related]

  • 2. Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin.
    Bregani ER, Lissoni P, Rossini F, Barni S, Tancini G, Brivio F, Conti A, Maestroni GJ.
    Recenti Prog Med; 1995 Jun; 86(6):231-3. PubMed ID: 7624582
    [Abstract] [Full Text] [Related]

  • 3. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
    Lissoni P, Bolis S, Brivio F, Fumagalli L.
    Anticancer Res; 2000 Jun; 20(3B):2103-5. PubMed ID: 10928160
    [Abstract] [Full Text] [Related]

  • 4. Immunological effects of a single evening subcutaneous injection of low-dose interleukin-2 in association with the pineal hormone melatonin in advanced cancer patients.
    Lissoni P, Barni S, Ardizzoia A, Brivio F, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1992 Jun; 6(4):132-6. PubMed ID: 1296454
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
    Lissoni P, Fumagalli L, Paolorossi F, Rovelli F, Roselli MG, Maestroni GJ.
    J Biol Regul Homeost Agents; 1997 Jun; 11(3):119-22. PubMed ID: 9498162
    [Abstract] [Full Text] [Related]

  • 7. Immune effects of preoperative immunotherapy with high-dose subcutaneous interleukin-2 versus neuroimmunotherapy with low-dose interleukin-2 plus the neurohormone melatonin in gastrointestinal tract tumor patients.
    Lissoni P, Brivio F, Brivio O, Fumagalli L, Gramazio F, Rossi M, Emanuelli G, Alderi G, Lavorato F.
    J Biol Regul Homeost Agents; 1995 Jun; 9(1):31-3. PubMed ID: 8553906
    [Abstract] [Full Text] [Related]

  • 8. The pineal hormone melatonin in hematology and its potential efficacy in the treatment of thrombocytopenia.
    Lissoni P, Tancini G, Barni S, Paolorossi F, Rossini F, Maffé P, Di Bella L.
    Recenti Prog Med; 1996 Dec; 87(12):582-5. PubMed ID: 9066251
    [Abstract] [Full Text] [Related]

  • 9. A biological study on the efficacy of low-dose subcutaneous interleukin-2 plus melatonin in the treatment of cancer-related thrombocytopenia.
    Lissoni P, Barni S, Brivio F, Rossini F, Fumagalli L, Ardizzoia A, Tancini G.
    Oncology; 1995 Dec; 52(5):360-2. PubMed ID: 7637951
    [Abstract] [Full Text] [Related]

  • 10. Cancer immunotherapy with low-dose interleukin-2 subcutaneous administration: potential efficacy in most solid tumor histotypes by a concomitant treatment with the pineal hormone melatonin.
    Lissoni P, Barni S, Ardizzoia A, Olivini G, Brivio F, Tisi E, Tancini G, Characiejus D, Kothari L.
    J Biol Regul Homeost Agents; 1993 Dec; 7(4):121-5. PubMed ID: 8023699
    [Abstract] [Full Text] [Related]

  • 11. Amplification of eosinophilia by melatonin during the immunotherapy of cancer with interleukin-2.
    Lissoni P, Ardizzoia A, Tisi E, Rossini F, Barni S, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1993 Dec; 7(1):34-6. PubMed ID: 8346714
    [Abstract] [Full Text] [Related]

  • 12. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
    Lissoni P, Brivio F, Fumagalli L, Messina G, Vigoré L, Parolini D, Colciago M, Rovelli F.
    Anticancer Res; 2008 Dec; 28(2B):1377-81. PubMed ID: 18505083
    [Abstract] [Full Text] [Related]

  • 13. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
    Lissoni P, Vaghi M, Ardizzoia A, Malugani F, Fumagalli E, Bordin V, Fumagalli L, Bordoni A, Mengo S, Gardani GS, Tancini G.
    In Vivo; 2002 Dec; 16(2):93-6. PubMed ID: 12073777
    [Abstract] [Full Text] [Related]

  • 14. Interleukin-2, melatonin and interleukin-12 as a possible neuroimmune combination in the biotherapy of cancer.
    Lissoni P, Pittalis S, Rovelli F, Vigorè L, Roselli MG, Brivio F.
    J Biol Regul Homeost Agents; 1995 Dec; 9(2):63-6. PubMed ID: 9127635
    [Abstract] [Full Text] [Related]

  • 15. Preliminary study on modulation of the biological effects of tumor necrosis factor-alpha in advanced cancer patients by the pineal hormone melatonin.
    Brackowski R, Zubelewicz B, Romanowski W, Lissoni P, Barni S, Tancini G, Maestroni GJ.
    J Biol Regul Homeost Agents; 1994 Dec; 8(3):77-80. PubMed ID: 7754792
    [Abstract] [Full Text] [Related]

  • 16. Neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin in AIDS patients with CD4 cell number below 200/mm3: a biological phase-II study.
    Lissoni P, Vigorè L, Rescaldani R, Rovelli F, Brivio F, Giani L, Barni S, Tancini G, Ardizzoia A, Viganò MG.
    J Biol Regul Homeost Agents; 1995 Dec; 9(4):155-8. PubMed ID: 8844341
    [Abstract] [Full Text] [Related]

  • 17. Neuroimmunotherapy of human cancer with interleukin-2 and the neurohormone melatonin: its efficacy in preventing hypotension.
    Lissoni P, Brivio F, Barni S, Tancini G, Cattaneo G, Archili C, Conti A, Maestroni GJ.
    Anticancer Res; 1990 Dec; 10(6):1759-61. PubMed ID: 2285255
    [Abstract] [Full Text] [Related]

  • 18. Modulation of interleukin-2-induced macrophage activation in cancer patients by the pineal hormone melatonin.
    Lissoni P, Tisi E, Brivio F, Ardizzoia A, Crispino S, Barni S, Tancini G, Conti A, Maestroni GJ.
    J Biol Regul Homeost Agents; 1991 Dec; 5(4):154-6. PubMed ID: 1803863
    [Abstract] [Full Text] [Related]

  • 19. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
    Lissoni P, Barni S, Tancini G, Ardizzoia A, Ricci G, Aldeghi R, Brivio F, Tisi E, Rovelli F, Rescaldani R.
    Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P, Rovelli F, Baiocco N, Tangini G, Fumagalli L.
    Anticancer Res; 2001 Jan; 21(1B):777-9. PubMed ID: 11299843
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.